Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.62 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | TNF | P01375 | 2/20 | 0.52 |
| ▸ | IL1B | P01584 | 2/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000098 | 0.86 | TSHR (0.53) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL29314096 | 0.83 | CRBN (0.48) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL25124027 | 0.81 | CRBN (0.58) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL23535313 | 0.79 | CRBN (0.59) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| Supidimide SCHEMBL828138 | 0.78 | TSHR (0.56) | TSHRALDH1A1TDP1 | |
| Thalidomide SCHEMBL455269 | 0.77 | CRBN (1.00) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| Thalidomide SCHEMBL7581 | 0.77 | CRBN (1.00) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| Thalidomide SCHEMBL411178 | 0.77 | CRBN (1.00) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| Thalidomide SCHEMBL411175 | 0.77 | CRBN (1.00) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| Thalidomide SCHEMBL15197560 | 0.77 | CRBN (1.00) | CRBNDDB1IKZF3TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11964945-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-0550112-A1 | 2-Saccharinylmethyl aryl and aryloxy acetates useful as proteolytic enzyme inhibitors and pharmaceutical compositions contaning them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0550111-A1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0549073-A1 | Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0542372-A1 | 2-Substituted saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | disclosed |
| US-5187173-A | Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders | STERLING WINTHROP INC. (US) | 1993-02-16 | — | — | US | disclosed |
| US-5128339-A | Emphysema, rheumatoid arthritis, pancreatitis | STERLING WINTHROP INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0483928-A1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use | STERLING WINTHROP INC. (US) | 1992-05-06 | — | — | EP | disclosed |
| EP-0471756-A4 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF | — | 1992-04-08 | — | — | EP | disclosed |
| EP-0471756-A1 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF. | STERLING WINTHROP INC (US) | 1992-02-26 | — | — | EP | disclosed |
| WO-1990013549-A1 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF | STERLING WINTHROP INC. (US) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CRBN 3/4885DDB1 433/4885IKZF3 3470/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | CRBN 5/4885DDB1 594/4885IKZF3 719/4885 |
| US-11964945-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | CRBN 3/4885DDB1 746/4885IKZF3 3010/4885 |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | CRBN 3/4885DDB1 750/4885IKZF3 3015/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | CRBN 1/4885DDB1 256/4885IKZF3 208/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | CRBN 3/4885DDB1 809/4885IKZF3 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.